Syneos Health, Inc. (SYNH) Announces Proposed 7M Secondary Offering
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Syneos Health Announces Secondary Offering of Common Stock
March 1, 2021 6:44 AM ESTMORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the Company or Syneos Health), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the Selling Stockholders) of an aggregate of 7,000,000 shares of the Companys common stock (the Offering) pursuant to the Companys shelf registration statement filed with the Securities and Exchange Commission (SEC). The Selling Stockholders intend to grant the underwriter a 30-day... More